Strategic Partnerships Immunome is actively expanding collaboration potential as evidenced by partnerships in 2026 and a recent Infinimmune collaboration, presenting clear opportunities for BD outreach to co-develop or co-commercialize ADC programs and leverage joint development efforts.

Late-Stage Push With varegacestat advancing to NDA submission for desmoid tumors and other late-stage programs in the pipeline, there is a clear selling window for companion diagnostics, ecosystem tools, and services supporting regulatory submissions, trial planning, and payer strategies.

Clinical Expertise Leadership with a track record in designing and commercializing targeted cancer therapies presents a strong case for high-touch engagements around advisory roles, strategic planning, and contract research or advisory services for ADC development.

Data and Tech Utilizing tools like Snowflake, Alteryx, and cloud platforms signals readiness for data collaboration, analytics services, and platform integrations that can enhance biomarker discovery, trial analytics, and real-world evidence generation.

Investor & Events Regular participation in high-profile conferences and investor events (JPMorgan, Goldman Sachs, NDA filings) indicates ideal timing for investor-focused partnerships, sponsored demonstrations, and targeted outreach to potential research and manufacturing partners.